A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy

Vaccine

Volumn 24, Issue 31-32, 2006, Pages 5862-5871

  Cho, Yang Je ^a,b   Ahn, Bo Young ^b   Lee, Na Gyong ^c   Lee, Dong Hyeon ^d   Kim, Doo Sik ^a  

^a Yonsei University   (South Korea)

^b EyeGene Inc   (South Korea)

^c Sejong University   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

Author keywords

Antitumor activity; Bacterial DNA fragments; Lipopolysaccharide

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL DNA; BCG VACCINE; CARBOHYDRATE; CIA 07; DNA FRAGMENT; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BLADDER CANCER; BLOOD CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; GUINEA PIG; HYDROLYSIS; IMMUNOSTIMULATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA, BACTERIAL; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; URINARY BLADDER NEOPLASMS;

EID: 33745383486     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.048     Document Type: Article

References (50)

1. Coley W.B. The treatment of inoperable malignant tumors with the toxins of erysipelas and the Bacillus prodigious. Am J Med Sci 108 (1894) 50-68
2. Hoption Cann S.A., van Netten J.P., and van Netten C. Dr William Coley and tumor regression: a place in history or in the future. Postgrad Med J 79 (2003) 672-680
3. Mizuno D., and Soma G. Oral or percutaneous administration of lipopolysaccharide of small molecular size may cure various intractable diseases: a new version of Coley's toxin. Mol Biother 4 (1992) 66-69
4. Starnes C.O. Coley's toxin in perspective. Nature 357 (1992) 11-12
5. Inagawa H., Nishizawa T., Noguchi K., Minamimura M., Takagi K., Goto S., et al. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 17 (1997) 2153-2158
6. Shimizu T., Iida K., Iwamoto Y., Yanagihara Y., Ryoyama K., Asahara T., et al. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol 17 (1995) 425-431
7. Hino M., Kohchi C., Nishizawa T., Yoshida A., Nakata K., Inagawa H., et al. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Anticancer Res 25 (2005) 3747-3754
8. Beutler B. Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr Opin Microbiol 3 (2000) 23-28
9. van de Wiel P.A., van der Pijl A., and Bloksma N. Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity. Cancer Immunol Immunother 33 (1991) 115-120
10. Dighe A.S., Richards E., Old L.J., and Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456
11. Bowie A., and O'Neil L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukocyte Biol 67 (2002) 508-514
12. Inagawa H., Nishizawa T., Honda T., Nakamoto T., Takagi K., and Soma G. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 18 (1998) 3957-3964
13. de Bono J.S., Dalgleish A.G., Carmichael J., Diffley J., Lofts F.J., Fyffe D., et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6 (2000) 397-405
14. Otto F., Schmid P., Mackensen A., Wehr U., Seiz A., Braun M., et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J cancer 32A (1996) 1712-1718
15. Akira S., Takeda K., and Kaisho T. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
16. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
17. Weiner G.J. Immunostimulatory DNA sequences and cancer therapy. Springer Semin Immunopathol 22 (2000) 107-116
18. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
19. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169 (2002) 3892-3899
20. Weigel B.J., Rodeberg D.A., Krieg A.M., and Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9 (2003) 3105-3114
21. Milas L., Mason K.A., Ariga H., Hunter N., Neal R., Valdecanas D., et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64 (2004) 5074-5077
22. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746
23. Zhao Q., Temsamani J., Iadarola P.L., Jiang Z., and Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 51 (1995) 173-182
24. Leifer C.A., Verthelyi D., and Klinman D.M. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 26 (2003) 313-319
25. Wang H., Rayburn E., and Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des 11 (2005) 2889-2907
26. Roberts T.L., Dunn J.A., Terry T.D., Jennings M.P., Hume D.A., Sweet M.J., et al. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 175 (2005) 3569-3576
27. Pichyangkul S., Yongvanitchit K., Kum-arb U., Krieg A.M., Heppner D.G., and Walsh D.S. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods 247 (2001) 83-94
28. Bhattacharjee A.K., Opal S.M., Taylor R., Naso R., Semenuk M., Zollinger W.D., et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis 173 (1996) 1157-1163
29. Lee C.H., and Tsai C.M. Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 267 (1999) 161-168
30. Montbriand P.M., and Malone R.W. Improved method for the removal of endotoxin from DNA. J Biotechnol 44 (1996) 43-46
31. Sher M.J., Tuner F.C., and Perrault A. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 4 (1943) 81-97
32. FitzGerald D.J., Kreitman R., Wilson W., Squires D., and Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 293 (2004) 577-582
33. Pastan I., and Kreitman R.J. Immunotoxins for targeted cancer therapy. Curr Opin Investig Drugs 3 (2002) 1089-1091
34. Niwa M., Milner K.C., Ribi E., and Rudbach J.A. Alteration of physical, chemical, and biological properties of endotoxin by treatment with mild alkali. J Bacteriol 97 (1969) 1069-1077
35. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 (1975) 3666-3670
36. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54 (2005) 721-728
37. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4 (2003) 565-573
38. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
39. Choo M.K., Sakurai H., Koizumi K., and Saiki I. Stimulation of cultured colon 26 cells with TNF-alpha promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett 230 (2005) 47-56
40. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164 (2000) 617-624
41. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts?. Nat Med 9 (2003) 831-835
42. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36 (1992) 983-997
43. Street S.E., Cretney E., and Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001) 192-197
44. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
45. Horinaga M., Harsch K.M., Fukuyama R., Heston W., and Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 66 (2005) 461-466
46. Riemensberger J., Bohle A., and Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127 (2002) 20-26
47. Sparwasser T., Miethke T., Lipford G., Borschert K., Hacker H., Heeg K., et al. Bacterial DNA causes septic shock. Nature 86 (1997) 336-337
48. Gao J.J., Xue Q., Papasian C.J., and Morrison D.C. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 166 (2001) 6855-6860
49. Yi A.K., Yoon J.G., Hong S.C., Redford T.W., and Krieg A.M. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappa B. Int Immunol 13 (2001) 1391-1404
50. Tinazzi E., Ficarra V., Simeoni S., Artibani W., and Lunardi C. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 12 (2005) 1-8